



## DRUG UTILIZATION REVIEW BOARD MEETING AGENDA

<u>Date</u>	<u>Time</u>	<u>Location</u>
April 20, 2023	10:00am – 3:00pm (CT)	Howerton State Office Building Conference Room 202 Jefferson City, MO 65109

### **Additional Meeting Details**

The meeting will have both in-person and virtual attendance options. Due to strict capacity limits, public attendance will be based on a first come/first serve sign-up, with a limit of **1 individual per organization**. Those unable to join in-person may listen in/provide public comment via Webex. Individuals wishing to attend in-person must contact **Carmen Burton** at [Carmen.M.Burton@dss.mo.gov](mailto:Carmen.M.Burton@dss.mo.gov) or call (573) 751-6961.

[Join Webex Meeting](#)

Meeting number (access code): 2465 924 2062

Meeting password: edSpRX9m85

**Join from a Video System/Application**

Dial [24659242062](tel:24659242062) @[stateofmo.webex.com](https://stateofmo.webex.com)

Or dial 173.243.2.68 and enter the meeting number.

**Join from a Mobile Device (attendees only)**

[1-650-479-3207](tel:16504793207) Call-in toll number (US/Canada)

**\* Click HERE for Meeting Documents \***

### **Opening Statements/Updates**

10:00 – 10:10	Welcome, Announcements and Introductions	Chairperson
10:10 – 10:20	Minutes Review	Discussion/Approval
10:20 – 10:30	Nominations and Election of Drug Utilization Review Board Chair	Josh Moore
10:30 – 10:40	Pharmacy Program/Budget Update	Elizabeth Short
10:40 – 10:50	Review of Prior Authorization Meeting and Public Hearing	Josh Moore

### **Old Business**

10:50 – 11:00	Implementation Schedule – Criteria for Previously Approved Clinical Edits, Step Therapies and PA's	Josh Moore
---------------	--	------------

### **New Business**

11:00 – 11:10	Proposed Actions – New Drug/Product Review	Olivia Rush
	i. Open Access	
	ii. Clinical Edit/Step Therapy	
	iii. Resource List	
	iv. PDL Agents	
	v. Prior Authorization	

### **Clinical and Fiscal Edit Review**

11:10 – 12:00	<u>Existing Criteria</u>	Josh Moore
	i. Acne or Rosacea, Select Topical Agents	
	ii. Fabry Disease	
	iii. Givlaari	
	iv. Imcivree	
	v. Isturisa	

- vi. Megestrol
- vii. Nulibry
- viii. Oxervate
- ix. Oxlumo
- x. Scenesse
- xi. Sick Cell Disease
- xii. Spravato
- xiii. Systemic Antifungals
- xiv. Tavneos
- xv. Voxzogo
- xvi. Zokinvy
- xvii. Zulresso

New Criteria or Revision of Existing Criteria

- i. Hemgenix
- ii. Tzield

**Break**

12:00 – 12:30 Lunch

**Preferred Drug List Edit Review**

12:30 – 1:30 Existing Criteria Josh Moore

- i. Actinic Keratosis Agents, Topical
- ii. Androgenic Agents
- iii. Antibiotics, Inhaled
- iv. Anticholinergics, LABA Combinations
- v. Anticholinergics, Short Acting and Combinations Inhaled
- vi. Antifungals, Topical
- vii. Antihistamines & Antihistamine/Decongestant Combinations, 2<sup>nd</sup> Generation
- viii. Antihistamines, Intranasal
- ix. Antiparasitics, Topical
- x. Antivirals, Herpes Oral
- xi. Benzoyl Peroxide/Antibiotic Combinations
- xii. Beta Adrenergic Agents, Nebulized
- xiii. Beta Adrenergic Agents, Short Acting
- xiv. Corticosteroids, Ophthalmic Soft
- xv. Corticosteroids, Oral Inhaled
- xvi. Corticosteroids, Topical
- xvii. Cough/Cold Preparations
- xviii. Fluoroquinolones, Ophthalmic
- xix. Fluoroquinolones, Otic
- xx. Hepatitis C Agents
- xxi. Leukotriene Receptor Modifiers
- xxii. Mast Cell Stabilizers, Ophthalmic
- xxiii. NSAIDs, Ophthalmic
- xxiv. Pancreatic Enzymes
- xxv. Retinoids, Topical

New Criteria or Revision of Existing Criteria

- i. Anticholinergics, LABAs/ICS Combinations and PDE4 Inhibitors
- ii. Anticholinergics, Long Acting Inhaled
- iii. Antifungals, Oral
- iv. Antihistamines, Ophthalmic
- v. Antivirals, Topical

- vi. Beta Adrenergic Agents, Long Acting
- vii. Corticosteroids & Rhinitis Agents, Intranasal
- viii. Epinephrine Agents, Self-Injectable
- ix. Glaucoma Agents
- x. Inflammatory Bowel Disease Agents, Oral
- xi. Inflammatory Bowel Disease Agents, Rectal

### Program Utilization Information

1:30 – 1:45	Conduent Reports	Jennifer Colozza
	<ul style="list-style-type: none"> <li>i. Call Center Statistics</li> <li>ii. Missouri SmartPA POS Transparency Report</li> <li>iii. “Top 25” Drugs by Cost/Claims</li> </ul>	
1:45 – 2:15	Conduent Retro DUR Report	Dimple Patel

### Other Business/Closing Comments

2:15 – 2:30	Other Business	Josh Moore
	<ul style="list-style-type: none"> <li>i. Discussion on best day of the week for meetings in the future</li> </ul>	

### Executive Session

2:30 – 3:00	Data Analysis	Josh Moore
-------------	---------------	------------

*Informal comments will be accepted from members of the audience at various points in the agenda.  
Times noted are approximate, agenda may move more quickly.*

### Next Meeting: July 20, 2023

Meeting location and attendance options subject to change

Howerton Building, Room 202  
615 Howerton Court  
Jefferson City, MO 65109  
*Public attendance may be limited*

Webex

***Motion to Close:*** *I move that this meeting be closed, and that all records and votes pertaining to and/or resulting from this closed meeting be closed, under Section 610.021 Subsection (14),(5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees.*

**Missouri Board of Pharmacy approved for 5 hours (0.5 CEU) of pharmacy continuing education.**

Webinar Attendees: In order to receive continuing education you must enter the webinar with your name as it appears on your Missouri Pharmacist License to earn credit. You must also email your name as it appears on your Missouri Pharmacist License, mailing address and Missouri pharmacist license number to MO HealthNet Pharmacy Scheduler (MHD.PHARMACYSCHEDULER@dss.mo.gov) within 24 hours after the conclusion of the meeting to earn credit with the subject "MHD Drug Utilization Review Board 4/20/23 CE Application". Incomplete submissions will not be processed.

In-Person Attendees: In order to receive continuing education you must sign in with your name as it appears on your Missouri Pharmacist License to earn credit. You must also email your name as it appears on your Missouri Pharmacist License, mailing address and Missouri pharmacist license number to MO HealthNet Pharmacy Scheduler (MHD.PHARMACYSCHEDULER@dss.mo.gov) within 24 hours after the conclusion of the meeting to earn credit with the subject "MHD Drug Utilization Review Board 4/20/23 CE Application". Incomplete submissions will not be processed.

CE credit is not submitted to the CPE Monitor.

Certificates will be emailed within 30 days of the meeting. You must save your certificates in case of audit by the Missouri Board of Pharmacy.

CE credit is only valid toward Missouri Board of Pharmacy licensure renewal.